LetroHEXAL® 2,5 mg

Description

Indications

• Early-stage hormone receptor-positive breast cancer in postmenopausal women as adjuvant therapy.
• Early-stage breast cancer in postmenopausal women after completion of standard adjuvant therapy with tamoxifen as extended adjuvant therapy.
• Advanced hormone-dependent breast cancer in postmenopausal women as 1st-line therapy.
• Disseminated breast cancer progressing on anti-estrogen therapy in postmenopausal women.

Contraindications

Hypersensitivity to letrozole or any other component of the drug.
Endocrine status characteristic of the reproductive period.
Pregnancy, lactation period.
Children under 18 years of age.
With caution

Chronic renal failure with creatinine clearance less than 10 ml/min.